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Abstract
Background: Identifying latent tuberculosis infection (LTBI) in people migrating from TB endemic regions to low incidence
countries is an important control measure. However, no prospective longitudinal comparisons between diagnostic tests
used in such migrant populations are available.
Objectives: To compare commercial interferon (IFN)-gamma release assays (IGRAs) and the tuberculin skin test (TST) for
diagnosing LTBI in a migrant population, and the influence of antecedent TST and LTBI treatment on IGRA performance.
Materials and Methods: This cohort study, performed from February to September 2012, assessed longitudinal IGRA and
TST responses in Nepalese military recruits recently arrived in the UK. Concomitant T-SPOT.TB, QFT-GIT and TST were
performed on day 0, with IGRAs repeated 7 and 200 days later, following treatment for LTBI if necessary.
Results:
individuals by QFT-GIT. There was substantial agreement between TST and T-SPOT.TB positives at baseline (71.4%
agreement; k= 0.62; 95% CI:0.44–0.79), but only moderate concordance between positive IGRAs (38.1% agreement;
k= 0.46; 95% CI:0.25–0.67). When reassessed 7 days following TST, numbers of IGRA-positive individuals changed from 8
to 23 for QFT-GIT (p = 0.0074) and from 21 to 23 for T-SPOT.TB (p=0.87). This resulted in an increase in IGRA concordance
to substantial (64.3% agreement; k=0.73; 95% CI:0.58-0.88). Thus, in total on day 0 and day 7 after testing, 29 out of 166
participants (17.5%) provided a positive IGRA and of these 13 were TST negative. Two hundred days after the study
commenced and three months after treatment for LTBI was completed by those who were given chemoprophylaxis,
23 and 21 participants were positive by T-SPOT.TB or QFT-GIT respectively. When individual responses were examined
longitudinally within this population 35% of the day 7 QFT-GIT-positive, and 19% T-SPOT.TB-positive individuals, were
negative by IGRA. When the change in the levels of secreted IFN-  was examined after chemoprophylaxis the medianc
levels were found to have fallen dramatically by 77.3% from a pre-treatment median concentration of IFN- 2.7 3c
IU/ml to a post-treatment median concentration IFN-c 0.62 (p = 0.0002).
Conclusions: This study suggests differences in the capacity of commercially available IGRAs to identify LTBI in the absence
of antecedent TST and that IGRAs, in the time periods examined, may not be the optimal tests to determine the success of
chemoprophylaxis for LTBI.
Citation: O’Shea MK, Fletcher TE, Beeching NJ, Dedicoat M, Spence D, et al. (2014) Tuberculin Skin Testing and Treatment Modulates Interferon-Gamma Release
Assay Results for Latent Tuberculosis in Migrants. PLoS ONE 9(5): e97366. doi:10.1371/journal.pone.0097366
Editor: Gernot G.U. Rohde, Maastricht University Medical Center (MUMC), Netherlands
Received January 14, 2014; Accepted April 17, 2014; Published May 9, 2014
Copyright:  2014 O’Shea et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding was received from the UK Surgeon General and the Drummond Foundation. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: a.f.cunningham@bham.ac.uk
Introduction
The effective control and elimination of tuberculosis (TB) in
low-incidence countries requires the prompt identification of
individuals with active and latent TB infection (LTBI). This latter
group has the potential to reactivate their infection, progress to
disease and transmit the organism to others. In the United
Kingdom (UK), TB notifications have increased to a plateau of
9,000 new cases per year of which .70% now occur in foreign-
born individuals, in whom the incidence rate of TB is .20 times
higher than among those born in the UK [1]. Therefore, effective
assessment of LTBI in migrant populations is of significant health
and social importance.
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Nonetheless, the diagnosis of LTBI remains challenging. Until
recently, the tuberculin skin test (TST) was the diagnostic method
of choice for LTBI. Although cheap and easy to perform, TST has
limited sensitivity and specificity and is not suitable for repeat
testing [2,3]. Recently, interferon- c) production from
Mycobacterium tuberculosis (M.tb)-specific
c
release assays (IGRAs). IGRAs have some advantages over TST
including the speed in which results are obtained, theoretical 
´rin (BCG) vaccine
There are multiple strategies for diagnosing LTBI. Some
countries recommend a single-step IGRA-based LTBI screening
strategy, whilst others advocate a primary TST and subsequent
IGRA in TST-positive individuals, which is the current UK
recommendation [15–18]. Limited data exist for direct compar-
ison between TST and commercially available IGRAs for
diagnosing LTBI in migrant populations. Available data have
indicated that lower detection rates are found using QFT-GIT
than T-SPOT.TB, but that both assays are potentially less
sensitive than TST [19]. Moreover, it remains unclear what the
impact of antecedent TST, which includes antigens used in
IGRAs, is on subsequent IGRA results and this important question
remains to be fully elucidated [10,20–27].
Once LTBI has been diagnosed and treated, clear correlates
that identify whether treatment has been successful, or not, are
desirable yet sadly lacking [28]. Data suggest that following
successful treatment of active disease, mycobacterial antigen load
declines and with it the frequency of effector T cells [29–33]. This
indicates that the quantification of T cell responses to M.tb-specific
antigens may also provide some correlative measure of bacterial
burden and so help determine the effectiveness of anti-tuberculosis
treatment [30]. Nevertheless, changes in IGRA measurements do
not correlate with classical sputum markers of bacillary burden in
active disease and do not necessarily change after treatment for
active disease or LTBI [34–37]. More data are needed to
For almost two centuries the British Army has recruited young
Nepalese males into the Gurkha regiment. Nepal is a region of
high TB endemicity with an incidence of 163 cases per 100,000
population per year and before leaving Nepal for the UK, recruits
are examined to exclude active TB disease. In the UK they are
further assessed for LTBI. This provides a unique opportunity to
examine IGRA responses longitudinally, with and without
chemoprophylaxis, in a well-defined cohort of individuals, whose
environmental experiences are controlled in a manner not
normally possible in civilian populations. Additionally, all individ-
uals can be sampled in parallel on the same day. This synchronous
processing enables direct comparisons to be made between IGRAs
and TST in the same patient cohort and whether chemoprophy-
laxis influences subsequent IGRAs and offers an opportunity to
optimally diagnose LTBI in populations of migrants leaving
countries of relatively high TB incidence to a country of low TB
incidence. The objectives of the current study were to examine the
longitudinal IGRA responses in Gurkha recruits after recent entry
into the UK and the effect of TST and chemoprophylaxis on the
results obtained.
Materials and Methods
Ethics, study design & population
Ethical approval was granted by the Ministry of Defence
Research Ethics Committee (MODREC 237/PPE/11). This was
a prospective, longitudinal cohort study among Nepalese military
recruits who had left Nepal and recently entered the UK.
Inclusion criteria included age at enrolment of $18 years and
exclusion of active TB disease, and in accordance with current
military and UK migrant screening policy, HIV status was not
assessed. The estimated prevalence of HIV infection among adults
aged 15–49 years in Nepal is 0.3% [38]. The Nepalese vaccination
policy for TB is to immunize once at birth with BCG. The full
study schedule is shown in Figure 1. Of the 176 Gurkha recruits
arriving in the UK in 2012, 166 fulfilled the inclusion criteria,
agreed to participate and provided written informed consent.
IGRA testing of recruits in the UK
Two commercially available assays were used - The Quanti-
FERON-TB Gold In-Tube (QFT-GIT; Cellestis, Carnegie,
Australia) whole blood enzyme-linked immunosorbent assay
(ELISA), and the T-SPOT.TB assay (Oxford Immunotec,
Abingdon, UK) enzyme-linked immunospot (ELISPOT) assay
using peripheral blood mononuclear cells (PBMCs). Peripheral
venous blood samples were provided at the first visit (day 0), and
on days 7 and 200. Samples were transported to Oxford
Immunotec’s diagnostic laboratory for the T-SPOT.TB assay
within 24 hours and the Health Protection Agency regional
Figure 1. Study flow diagram of screening and testing for
latent tuberculosis infection. At recruitment demographic data,
past medical history, previous TB disease, BCG vaccination status and
recent TB exposure were all recorded. TST = tuberculin skin test; QFT-
GIT = QuantiFERON Gold in-Tube.
doi:10.1371/journal.pone.0097366.g001
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determine whether altered T cell responses are relevant.
independence from prior Bacillus Calmette-Gue
exposure, and their potential for intra-patient repeat use [4–8].
Nevertheless, some issues remain for their use in diagnosing
LTBI, primarily relating to subject variability, reproducibility,
and the potential discordance between assays [9–14].
gamma (IFN-
T cells in response to the
early secretory antigenic target-6 (ESAT-6), culture filtrate protein-
10 (CFP-10) and TB7.7 antigens has been employed in IFN-
mycobacterial reference laboratory (Newcastle, UK) for the QFT-
GIT assay within 8 hours of collection.
Standard criteria for positive responses were used for both tests
as recommended by the manufacturers: for QFT-GIT, IFN-c
concentrations $0.35 IU/ml and $25% of the negative control
value, after correcting for negative control values; for T-
SPOT.TB, $6 SFCs/250,000 PBMCs to ESAT-6 or CFP-10,
adjusted for the negative control, except when the negative control
was $6 SFCs, whereupon SFCs of $ twice the negative control
were required. Between serial IGRAs, conversion to positivity was
defined as an initial IFN-c concentration of ,0.35 IU/ml or ,6
SFCs which increased to $0.35 IU/ml or $6 SFCs, respectively.
The opposite definition was used for reversion to negativity.
‘Borderline’ or ‘uncertainty’ zones have previously been defined as
0.2–0.7 IU/ml for QFT-GIT or 4–8 SFCs for T-SPOT.TB.
Conversion thresholds of an increase of ,0.2 to .0.7 IU/ml for
QFT-GIT and from ,6 to .9 SFCs for T-SPOT.TB, were also
applied in our analyses [11,25].
Tuberculin skin testing
On day 0, following blood sampling for the IGRAs, a TST was
performed by the Mantoux method. Two tuberculin units of strain
RT23 purified protein derivative (PPD, Statens Serum Institut,
Copenhagen, Denmark) was applied intradermally and transverse
induration measured 72 hours later. Positivity was defined as an
induration of $6 mm in BCG-naive and $15 mm in BCG-
vaccinated individuals in accordance with UK guidelines (stratified
threshold). We also used non-stratified threshold for TST
positivity, defined as induration $10 mm irrespective of BCG
vaccination history.
Treatment of LTBI
Individual’s positive for either IGRA at day 0 and/or day 7,
with normal chest radiography and no indication of active disease,
were defined as having LTBI and offered LTBI treatment.
Individuals who only provided a positive TST, but not a positive
IGRA, were not treated. A three month regimen of daily self-
administered weight-based, fixed-dose combination therapy of
rifampicin and isoniazid was prescribed in accordance with
current UK guidance [17].
Statistical Analysis
Data analyses were performed using GraphPad Prism. The two-
tailed Fisher’s exact test was used to compare categorical data and
the Mann-Whitney test (unpaired) or Wilcoxon signed rank test
(matched-pairs) for analysis. McNemar’s test was used to compare
paired proportions. Concordance between TST and IGRA results
was assessed using percentage agreement and Cohen’s k
coefficients; strength of agreement was considered ‘poor’ for k#
0.20, ‘fair’ for 0.20,k#0.40, ‘moderate’ for 0.40,k#0.60,
‘substantial’ for 0.60,k#0.80 and ‘optimal’ for 0.80,k#1.00
[39].
Results
Of 176 Gurkha recruits who arrived in the UK from Nepal, 166
volunteered to participate in the study. All participants were male,
aged 18–21 years and 105 had been vaccinated with BCG. No
participant reported a prior history of TB, known exposure to TB
or any other past medical history. All individuals enrolled at day 0
re-attended at days 3, 7 and 200 and provided a complete set of
samples (Figure 1). In each case the samples for each time-point
were obtained on the same day.
Differences in QFT-GIT and T-SPOT.TB tests to detect
anti-mycobacterial responses
The IGRA testing revealed that 21 individuals were T-
SPOT.TB positive (12.9%, two ‘borderline positive’) and eight
were QFT-GIT positive (4.8%). All QFT-GIT positives were also
T-SPOT.TB positive. Thus, 61.9% T-SPOT.TB positive partic-
ipants were QFT-GIT negative, meaning the tests showed
moderate agreement (90.4%; k=0.46; 95% CI:0.25–0.67)
(Table 1).
TST were performed at day 0 and read at day 3, and the results
compared to the day 0 IGRAs. There was substantial agreement
between TST and T-SPOT.TB and fair agreement between TST
and QFT-GIT (Table 1). Twenty-one (12.9%) individuals were
TST positive using a stratified threshold which increased to 26
(15.9%) with a non-stratified threshold, of whom 5 and 13 had
been BCG vaccinated (respectively). IGRA-positivity occurred at
all sizes of TST induration (Figure 2), whereas IGRA-negative
TST-positive individuals tended to have a lower induration.
Agreement between both IGRAs and TST was highest in BCG-
naive individuals and greater for T-SPOT.TB than for QFT-GIT
(Table 1). Therefore, T-SPOT.TB had a greater concordance with
TST than did QFT-GIT when performed prior to the TST.
There was a strong positive linear correlation between IFN-c and
ESAT-6 and CFP-10 responses among individuals positive by both
IGRAs at baseline (r2 = 0.88 and 0.95, respectively; Figure 3).
Antecedent TST augments IGRA concordance
To examine if the TST influenced the results of a subsequent
IGRA, repeat IGRAs were performed 7 days after TST
administration. Four (19.0%) of the 21 T-SPOT.TB positive
individuals at day 0 were no longer positive on repeat IGRA, two
of whom had been ‘borderline positive’ on day 0. Six (4.2%) of the
142 IGRA-negative individuals on day 0 became positive by T-
SPOT.TB, including one ‘borderline positive’ result, yielding a
total of 23 positives at day 7 (13.9%). One of six converters was
TST positive.
None of the eight day 0 positive QFT-GIT individuals reverted
to negativity. However 15 (9.5%) previously negative individuals
converted to positivity, nearly tripling the numbers of positive
individuals to 23 (13.9%) on day 7 (p = 0.0074). Of the 23 QFT-
GIT-positive individuals, nine were also TST-positive (60.0%
concordance). Three of six T-SPOT.TB converters also provided
positive QFT-GIT tests, thus increasing the agreement between
the IGRA tests and TST to substantial (k=0.62-0.63; 95%
CI:0.44–0.81) (Table 1). Concordance between T-SPOT.TB and
TST were similar at day 0 and 7, but the strength of agreement
between QFT-GIT and TST improved considerably at day 7 (day
0, k=0.37; 95% CI:0.14–0.60; day 7, k=0.63; 95% CI:0.46–
0.81). Agreement between QFT-GIT and T-SPOT.TB results at
day 7 also improved to 93.4% (k=0.73; 95% CI:0.58–0.88).
Combining the day 7 IGRA results gave a total of 29 positives
among the study population (17.5%). Concordant pairs (positive
by both IGRAs at day 7) occurred in 18 cases. Overall, intra-assay
agreement between day 0 and day 7 T-SPOT.TB results was
higher than for QFT-GIT results (k=0.66; 95% CI:0.50–0.83;
k=0.48; 95% CI:0.26–0.70, respectively) (Table 1). Therefore, an
antecedent TST was associated with a profound increase in QFT-
GIT IGRA detections.
Recent tuberculin exposure is associated with
augmented IGRA responses
Since antecedent TST could alter IGRA positivity we also
assessed whether the strength of the IGRA response was also
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affected. Changes in positive results were observed for both IGRA
tests and were often, though not always, associated with increased
numbers of results falling into the zones of uncertainty (Table 2).
The eight individuals positive by QFT-GIT at both day 0 and day
7 had enhanced IFN-c levels after the TST (day 0 median IFN-c
1.43 IU/ml, day 7 median IFN-c 7.67 IU/ml, p= 0.008). Of the
15 participants initially negative at day 0 by QFT-GIT but
subsequently positive after TST, there was a.15 fold increase in
IFN-c levels (Figure 4A; day 0 median IFN-c 0.09 IU/ml, day 7
median IFN-c 1.44 IU/ml, p =,0.0001). In contrast, in the 143
individuals QFT-GIT who remained negative at day 7 no change
in median IFN-c levels was observed (20.01 IU/ml both day 0
and 7, p= 0.85).
Among the six individuals converting to T-SPOT.TB positivity
at day 7, numbers of SFCs increased for both ESAT-6 and CFP-
10, with medians rising by up to 3-fold (ESAT-6 Day 0=2 SFCs/
well, day 7= 6 SFCs/well; CFP-10 Day 0=3.5 SFCs/well, Day
7= 10.5 SFCs/well, p = 0.03). Among the 17 T-SPOT.TB-posi-
tives at both day 0 and 7, median SFCs for each antigen over the
two sampling points remained relatively stable (ESAT-6 Day
Figure 2. The relationship between IGRA response and TST induration. The distribution of positive IGRAs (pre- and post-TST) by size of TST
induration. TST = tuberculin skin test; QFT-GIT = QuantiFERON Gold in-Tube.
doi:10.1371/journal.pone.0097366.g002
Figure 3. The relationship between the magnitude of IFN-c response among individuals positive by both IGRAs at baseline. Solid line
represents linear correlation. QFT-GIT = QuantiFERON Gold in-Tube; IFN-c= interferon-gamma; ESAT-6 = early secretory antigenic target-6; CFP-10 =
culture filtrate protein-10; IU = international units; SFC= spot forming cells.
doi:10.1371/journal.pone.0097366.g003
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0= 19 SFCs/well, Day 7= 21 SFCs/well; CFP-10 Day
0= 26 SFCs/well, Day 7= 32 SFCs/well). However, among the
eight individuals positive by both IGRAs at days 0 and 7 there was
augmentation in SFC numbers for both antigens, but particularly
to ESAT-6 (median SFCs/well to ESAT-6, day 0= 34, day
7= 145, p= 0.31; median SFCs/well to CFP-10, day 0= 36, day
7= 42, p= 0.38). There was no significant change in SFC numbers
in the 134 persistently negative individuals.
A significant proportion of the dynamic IGRA responses
(conversions and reversions) following TST occurred around the
zones of uncertainty for both assays (Table 2). However, even with
the application of very stringent definitions for conversion
thresholds, ‘true’ conversions did occur and more frequently with
the QFT-GIT than T-SPOT.TB assay (Figure 4B and C).
Treatment for LTBI does not alter a positive response in
most individuals
After excluding the presence of active disease, each of the 29
individuals considered positive for LTBI, by either one or both
IGRAs at either day 0 or day 7, underwent and completed
treatment without complication. Three months after completion
the whole cohort provided a third sample. Five of the 27
individuals who provided a positive T-SPOT.TB IGRA at day 0
or day 7 or both times reverted to negativity after they completed
treatment (18.5% vs 81.5%, p= 0.22). In those positive by T-
SPOT.TB, numbers of ESAT-6 or CFP-10 SFC were not
markedly different (Figure 5A and B). Of the 134 negative
individuals there was one conversion, though this was weak and in
the ‘uncertainty’ zone (data not shown). The agreement between
Figure 4. IGRA responses before and after TST administration. (A) IFN-c responses detected by QFT-GIT in individuals who became positive
following TST; (B) SFC numbers in response to ESAT-6 and CFP-10 in individuals who became positive by T-SPOT.TB following TST; (C) SFC numbers in
response to ESAT-6 and CFP-10 in individuals who became negative by T-SPOT.TB following TST. Uncertainty zone (grey shaded area); threshold for
QFT-GIT positivity (dashed line); upper and lower thresholds for T-SPOT.TB conversion (solid lines). TST = tuberculin skin test; QFT-GIT = QuantiFERON
Gold in-Tube; IFN-c= interferon-gamma; ESAT-6 = early secretory antigenic target-6; CFP-10= culture filtrate protein-10; IU = international units;
SFC = spot forming cells.
doi:10.1371/journal.pone.0097366.g004
Table 2. Frequency of IGRA conversions and reversions following TST administration and stratified by baseline QFT-GIT and T-
SPOT.TB responses.
Baseline IGRA response n TST positive n (%) IGRA positive Conversion frequency n (%) Reversion frequency n (%)
QFT-GIT IFN-c (IU/ml)
,0.01 112 5 (4.5) 3 (2.7) na
0.01–0.09 38 5 (13.2) 5 (13.2) na
0.1–0.19 6 3 (50.0) 5 (83.3) na
0.2–0.34 2 2 (100.0) 2 (100.0) na
0.35–0.69 1 1 (100.0) 1 na 0
0.7–0.9 0 0 0 na 0
1.0–2.9 5 3 (60.0) 5 na 0
3.0–5.9 1 1 (100.0) 1 na 0
6.0–10.0 1 1 (100.0) 1 na 0
Total 166 21 8 15 0
T-SPOT.TB
ESAT-6 (SFC/well)
0–3 141 10 (7.1) 2 (1.4) na
4–5 7 2 (28.6) 1 (14.3) na
6–8 3 0 (0.0) 1 na 1 (100)
9–29 6 4 (66.7) 4 na 0
$30 6 5 (83.3) 7 na 0
Total 163 21 12 3 1
CFP-10 (SFC/well)
0–3 130 6 (4.6) 2 (1.5) na
4–5 7 0 (0.0) 2 (28.6) na
6–8 8 3 (37.5) 5 1 (20.0) 2 (40.0)
9–29 10 5 (50.0) 8 na 2 (25.0)
$30 8 7 (87.5) 8 na 0
Total 163 21 21 5 4
IGRA = interferon-gamma release assay; TST = tuberculin skin test; QFT-GIT = QuantiFERON Gold in-Tube; IFN-c= interferon-gamma; ESAT-6 = early secretory antigenic
target-6; CFP-10 = culture filtrate protein-10; IU = international units; SFC = spot forming cells; na = not applicable. Note: n = 163 for T-SPOT.TB tests due to the
exclusion of three indeterminate results.
doi:10.1371/journal.pone.0097366.t002
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T-SPOT.TB results at day 7 and 200 improved to 96.4% with an
‘optimal’ concordance (k=0.86; 95% CI: 0.74–0.97).
Of the 23 individuals positive by QFT-GIT at either day 0 or
day 7 or both times, eight reverted to negativity after they had
completed their treatment. Median IFN-c levels decreased by
77.3% following treatment (pre-treatment median IFN-c 2.73 IU/
ml, post-treatment IFN-c 0.62, p = 0.0002). Of the eight individ-
uals initially positive at day 0, two became negative (median pre-
treatment IFN-c 7.67 IU/ml, post-treatment IFN-c 2.67 IU/ml,
p = 0.063), while of the 15 participants who became positive on
day 7 after the TST, 40% reverted (median pre-treatment IFN-c
1.44 IU/ml, post-treatment IFN-c 0.49 IU/ml, p = 0.0016)
(Figure 5C). Six of the 143 negative participants who did not
receive LTBI chemoprophylaxis were positive by QFT-GIT on
day 200 (day 7 median IFN-c 0.02 IU/ml, day 200 median IFN-c
0.49 IU/ml, p = 0.03), although four of these lay in the zones of
uncertainty. Concordance between QFT-GIT results pre- and
post-treatment was moderate (89.2%, k=0.53; 95% CI:0.34–
0.72), and overall agreement between QFT-GIT and T-SPOT.TB
results decreased slightly by day 200 to 88.6% (k=0.51; 95%
CI:0.32–0.70). Therefore, after treatment for LTBI, reductions in
IGRA responses, although not consistent, were most detectable in
the group positive by QFT-GIT.
Discussion
This study evaluated the performance of currently available
commercial IGRAs for the diagnosis of LTBI in a migrant
population, and how antecedent TST and LTBI treatment
influence these. The key strengths of this study are the cohort,
the similar population age and ethnicity, the assured adherence to
treatment, the synchronous manner in which samples were
collected and processed and the setting that controlled for TB
exposure.
At first presentation nearly three times more individual’s had
positive TST and T-SPOT.TB results than QFT-GIT results. For
all tests there was a greater concordance between an IGRA test
and TST in BCG-naive than BCG-vaccinated individuals
(Table 1), as previously described [7]. Using a non-stratified
threshold to interpret a TST increased the number of positives,
but many of these may have been false-positive as half had been
BCG-vaccinated. Thus non-stratification may over-estimate the
numbers of LTBI individuals, and that in light of results from
more specific tests such as IGRAs a stratified threshold may
provide a more discriminatory test.
A lack of a ‘gold standard’ test introduces difficulties in
evaluating the performance and diagnostic accuracy of assays for
detecting LTBI [40]. Comparison with previous studies is also
complicated by the heterogeneity in study designs. Nevertheless,
systematic reviews and meta-analyses suggest that compared with
the TST, IGRAs have a higher specificity for the diagnosis of
LTBI and follow up studies show that these tests are better at
predicting who will progress to disease [41]. Furthermore, whilst
TST specificity is altered after vaccination with BCG, this is not
the case for IGRAs and vaccination with BCG [42].
Multiple studies suggest that the T-SPOT.TB assay has a higher
sensitivity but somewhat lower specificity than QFT-GIT
[7,8,42,43]. A recent observational study of TST and IGRA
responses in migrants made the first three-way assessment of
screening methods [19]. This identified a ‘fair’ concordance
between TST and both IGRAs, and a ‘moderate’ concordance
between IGRAs, although simultaneous sampling for all tests was
not performed and comparative results were not available for 25%
of cases [19]. Clarifying what level of concordance between assays
is acceptable and clinically relevant is an important future
necessity.
Administration of PPD resulted in a marked increase in QFT-
GIT positive individuals, which was not seen for the T-SPOT.TB
test. It is unlikely the more numerous T-SPOT.TB positives at day
0 are false positives due to the greater overall diagnostic agreement
between TST and T-SPOT.TB results than between TST and
QFT-GIT. Additionally, longitudinal, intra-individual T-
SPOT.TB results were generally consistent and the TST resulted
in QFT-GIT results more reflecting those of the T-SPOT.TB test.
Technical factors are unlikely to have influenced QFT-GIT results
at day 0 because samples were collected, transported and
processed similarly each time. Also, controls were within expected
ranges, no indeterminate QFT-GIT results were recorded and the
assay was performed by a national TB reference laboratory. We
interpret these results to indicate that QFT-GIT has a lower
sensitivity for diagnosing LTBI and that tuberculin may enhance
the response in some individuals to this test. Further carefully
controlled studies are required to confirm these findings.
Results from IGRAs can be dynamic, producing transient
responses. Intra-subject variability can complicate their interpre-
tation, particularly for borderline cases, and may occur for reasons
including exposure to active TB cases and environmental NTM
[11,25,44]. In this study, such reasons may be less applicable as
participants were confined to a military training facility in a region
of England with a low incidence of TB and there was no contact
with active disease.
Our data suggest that by assessing IGRA responses before and
after TST, five distinct groups can be identified (Table 3). The first
two groups are those who are persistently negative or positive, by
both IGRAs, throughout the study. The persistently positive
results may be due to persisting or higher levels of antigen in
LTBI, and occasionally responses increased following further
antigenic challenge with PPD. In contrast to others we observed a
strong linear correlation between secreted IFN-c and ELISPOT
counts in response to both ESAT-6 and CFP-10 among this group
[45].
Among those who converted to positivity during the study we
believe there are two groups. The first is comprised of those
negative at baseline for both IGRAs and a second group that had
discordant IGRA results at baseline. Expansion of memory T cells
following PPD stimulation may account for conversion among the
first group. The differences in these groups may relate to the level
of bacterial burden or antigen availability and therefore the level
of immune stimulation. A low sensitivity assay or a weak immune
response may produce initial false negative results, which is
enhanced after further antigen exposure (i.e. PPD). Differences
between the whole-blood ELISA and PBMC ELISPOT may also
contribute to the inter-assay variation observed. The final, fifth
Figure 5. IGRA responses following LTBI treatment in individuals positive by IGRA at any stage of the study. (A) SFC numbers detected
to ESAT-6 by T-SPOT.TB; (B) SFC numbers detected to CFP-10 by T-SPOT.TB; bars = medians; (C) IFN-c responses detected by QFT-GIT in individuals
who were initially positive at day 0 compared to day 200 (left) and IFN-c responses detected by QFT-GIT in individuals who were positive at day 7
compared to day 200. In each case samples from the same individual at these two times are linked by bars. QFT-GIT = QuantiFERON Gold in-Tube;
IFN-c = interferon-gamma; ESAT-6 = early secretory antigenic target-6; CFP-10 = culture filtrate protein-10; IU = international units; SFC= spot
forming cells; Rx = treatment.
doi:10.1371/journal.pone.0097366.g005
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group of positive to negative reversions only occurred in
discordant individuals. One possible explanation is that this may
reflect transient exposure to M.tb prior to the study, with the results
reflecting weak responses declining with time [46]. It is also
possible that T cell frequency in peripheral blood is not constant or
other reasons such as co-infections modulating test results.
Following completion of treatment, 35% of QFT-GIT-positive
individuals reverted to negativity. Median IFN-c levels decreased
significantly in those treated but the change was most profound in
those who were positive only after antecedent TST and least
marked in those who were positive on day 0. In contrast, responses
in the T-SPOT.TB assay were much less affected by chemopro-
phylaxis. Previous studies have reported variable results for the T
cell response to ESAT-6 and CFP-10 in adults following treatment
for LTBI for reasons that may include the differing methodologies
used and populations examined between studies [28,35,36,47,48].
Nevertheless, collectively the data suggest that IGRAs alone are
sub-optimal tools to monitor the success of treatment for LTBI.
Numerous reasons could account for the persistent positivity or
modest reductions of IGRA responses following LTBI treatment
[48–52]. The most critical to understand is whether treatment
actually clears LTBI or if it simply enables better control of the
latent infection. There may also be differences in the rate of
decline of effector T cell numbers or their production of IFN-c,
possibly reflecting antigen persisting after bacillary death. None of
these reasons are mutually exclusive. Future studies are needed to
understand the kinetics of immunological responses in individuals
with LTBI and the levels of sterilization achieved by chemopro-
phylactic treatment.
There are a number of limitations to this study. First is the lack
of a true ‘gold standard’ for diagnosing LTBI which is an issue
shared with other studies in this field. Furthermore, there was no
untreated LTBI control group and also no regular, longitudinal
follow-up of individual patients. Additionally, although unlikely to
have any persisting effect, antecedent TST administration may
have confounded the response of an individual to treatment.
In summary, this study has examined the response in two
commercially available IGRAs for the diagnosis of LTBI in a
migrant population of Gurkha recruits. The study finds that in the
absence of a TST then more positive responses could be identified
by the T-SPOT.TB test than by QFT-GIT. Nevertheless, after a
recent TST the responsiveness to both tests was more similar,
mainly due to an increase in the numbers of positive QFT-GIT
responses. Follow-up IGRA testing for LTBI after treatment in
this population supports the current concept that monitoring of
IGRA responses in adults following completion of chemoprophy-
laxis is of speculative value only.
In light of the findings presented in this study the UK Ministry
of Defence has altered its policy for LTBI screening in Gurkha
recruits to the use of a single T-SPOT.TB IGRA [53]. These
findings are important because they have implications for LTBI
diagnostic strategies in populations of migrants arriving in
countries of low TB incidence from areas of high TB incidence.
This may also have some cost and time saving implications for
screening in non-military migrants in the U.K. and thus may help
to inform future UK guidance.
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